EMA recommends new diabetes treatments for approval


eMediNexus    28 January 2018

The European Medicines Agencys (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval a biosimilar of insulin glargine and three formulations of ertugliflozin, for type 2 diabetes viz. ertugliflozin monotherapy (Steglatro), fixed-dose ertugliflozin and metformin (Segluromet) and fixed-dose ertugliflozin and sitagliptin (Steglujan). All are indicated for adults aged 18 years and older with type 2 diabetes as adjuncts to diet and exercise to improve glycemic control.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.